Table 1.
Summary characteristics of individual included studies of patients with a Brugada syndrome
| Study (year) | Study design | N | Country | Men (%) | Mean age (years) | Symptomatic BrS (%) | Follow‐up (months) | Factors adjusted in analyses | Leads measured | Outcomes |
|---|---|---|---|---|---|---|---|---|---|---|
| de Asmundis et al, (2017) | Cohort | 289 | Belgium | 70.2 | 44.8 ± 16.0 | 35.6 | 120.6 ± 55.7 | N/A | V1‐V3 | SCD or appropriate shcok |
| Benito et al (2008) | Cohort | 384 | Spain, Belgium, and Canada | 70.8 | 45.9 ± 15.3 | 21.6 | 57.9 ± 48.8 | N/A | V2 | VF or SCD |
| Calò et al (2016) | Prospective cohort | 347 | Italy | 78.4 | 45.0 ± 13.1 | 20.5 | 48.0 ± 38.6 | N/A | V2 | VF or SCD |
| Conte et al (2013) | Retrospective cohort | 503 | Belgium | 58 | 40.7 ± 12.3 | 46 | 29 ± 8 | N/A | V1‐V2 | sVT or VF |
| Furushima et al (2005) | Case‐control | 24 | Japan | 95.8 | 60.0 ± 14.4 | 62.5 | 33 ± 16 | N/A | V1‐V2 | SCA |
| Ikeda et al (2005) | Prospective cohort | 124 | Japan | 94.4 | 50.0 ± 15.0 | 33.1 | 40.0 ± 19.0 | N/A | sVT, VF, or SCD | |
| Junttila et al (2008) | Case‐control | 200 | Findland, Belgium, China, Spain, and Canada | 71.20 | 40 ± 16 | 33 | N/A | Gender, age, and SCN5A mutation | sVT, VF, or SCD | |
| Kanda et al (2012) | Retrospective cohort | 34 | Japan | 97.1 | 43.5 ± 12.4 | 100 | 38 | N/A | V5‐V6 | VF or SCA |
| Kawata et al (2013) | Prospective cohort | 49 | Japan | 94 | 46.0 ± 12.7 | 35 | 93.8 ± 45.6 | N/A | N/A | VF or SCD |
| Kawazoe et al (2016) | Case‐control | 143 | Japan | 97.9 | 46.17 ± 12.7 | 32.9 | 82.8 ± 49.0 | N/A | V6 | VF |
| Makarawate et al (2017) | Prospective cohort | 40 | Thailand | 97.5 | 43.5 ± 12.7 | 100 | 28.3 ± 11.3 | N/A | N/A | Appropriate shock |
| Morita et al (2018) | Case‐control | 62 | Japan | 100 | 50.1 ± 10.9 | 22.6 | 27‐134 | N/A | V3 | VF |
| Nakano et al (2010) | Prospective cohort | 52 | Japan | 94.2 | 42 ± 3 | 34.6 | 39 + 4 | NA | V1‐V2 | VF |
| Nishii et al (2010) | Prospective cohort | 108 | Japan | 97.2 | 46.8 ± 11.6 | 38.9 | 71.9 ± 41.3 | N/A | V5 | VF |
| Park et al (2003) | 15 | Korea | 86.7 | 44 ± 10 | 87 | 19 ± 14 | N/A | N/A | VF | |
| Probst et al (2010) | Prospective cohort | 1029 | Italy, Germany, France and The Netherlands | 72 | 45 ± 5 | 36 | 40 ± 50 | N/A | N/A | SCA |
| Sieira et al (2017) | Retrospective cohort | 400 | Belgium | 58.3 | 41.1 ± 17.8 | 32.7 | 80.7 ± 57.2 | N/A | N/A | SCD |
| Takagi et al (2007) | Retrospective cohort | 188 | Japan | 94.7 | 53 ± 14 | 47.9 | 37 ± 16 | N/A | V6 | VF |
| Take et al (2012) | Retrospective cohort | 84 | Japan | 97.6 | 47 ± 12 | 48.8 | 48 ± 48 | N/A | SAEG | VF |
| Tokioka et al (2014) | Prospective cohort | 246 | Japan | 95.9 | 47.6 ± 13.6 | N/A | 45.1 ± 44.3 | N/A | V2 | SCD, VF |
| Yamagata et al (2017) | Prospective cohort | 415 | Japan | 97 | 46 ± 14 | 45.3 | 72 | N/A | V2 | Appropriate shock, SCA or SCD |
| Zumhagen et al (2016) | Retrospective cros‐section | 78 | Germany | 73.1 | 45 + 14 | 65.4 | N/A | N/A | V1 | sVT, VF, or SCD |
Abbreviations: N/A, not applicable; SCA, sudden cardiac arrest; SCD, sudden cardiac death; sVT, sustained ventricular tachycardia; VF, ventricular fibrillation.